Rheumatology

Systemic Lupus Erythematosus

Expert Perspectives in Systemic Lupus Erythematosus to Cover Key Topics in Systemic Lupus Erythematosus Treatment

expert perspectives by Bevra H. Hahn, MD; George C. Tsokos, MD; Joan T. Merrill, MD

Overview

Expert Perspectives delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medicine, in a concise and timely format. This issue of Expert Perspectives in Systemic Lupus Erythematosus will feature selected topics in Systemic Lupus Erythematosus that we hope you will find of value in your clinical practice.

The clinicians who were surveyed selected the following experts and topics.

Community-Selected Experts:

Bevra H. Hahn, MD

Professor of Medicine, Emeritus
Rheumatologist
UCLA School of Medicine
Los Angeles, CA

Joan T. Merrill, MD

Member and Director of Clinical Projects
Arthritis & Clinical Immunology Research Program
Oklahoma Medical Research Foundation
OMRF Professor of Medicine
University of Oklahoma Health Sciences Center
Adjunct Professor of Medicine
New York University Langone Health
Chief Advisor for Clinical Development
Lupus Foundation of America
Oklahoma City, OK

George C. Tsokos, MD

Professor of Medicine
Harvard Medical School
Chief, Division of Rheumatology and Clinical Immunology
Beth Israel Deaconess Medical Center
Boston, MA

Community-Selected Topics:

Expert Roundtables

•   Challenges in Systemic Lupus Erythematosus: Where Do We Stand?
•   Targeted Biologic Therapy in Systemic Lupus Erythematosus
•   Improving Long-term Outcomes in Systemic Lupus Erythematosus: Trends and Contributors
•   The Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: Preventing Early Damage

Clinical Topic Updates

•   Systemic Lupus Erythematosus: Treatments in Development
•   Interferon-Blocking Strategies in Systemic Lupus Erythematosus Research
•   Genetic Susceptibility to Common and Severe Manifestations of Systemic Lupus Erythematosus
•   Research on Drug-Induced Systemic Lupus Erythematosus Sheds Light on Autoimmunity

Patient Care Perspectives

•   Low-Dose Interleukin 2 and Its Potential in Systemic Lupus Erythematosus
•   Impact of COVID-19 in Systemic Lupus Erythematosus
•   Outcomes With B-Cell Activating Factor Inhibition in the Real-World Setting
•   Emerging Therapeutic Targets in Systemic Lupus Erythematosus: Treatment and Maintenance